11,938 Shares in Electromed, Inc. $ELMD Bought by AlphaQuest LLC

Key Points

• AlphaQuest LLC has acquired a new stake in Electromed, Inc. ($ELMD), purchasing 11,938 shares valued at approximately $285,000, representing 0.14% ownership.
• Institutional investors collectively own 40.82% of Electromed's stock, with significant investments made by firms like Raymond James and Barclays PLC during the previous quarters.
• Electromed shares have a consensus rating of "Buy" with an average target price of $36.25, following recent upgrades and adjustments from multiple analysts.

AlphaQuest LLC acquired a new position in shares of Electromed, Inc. (NYSE:ELMD - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 11,938 shares of the company's stock, valued at approximately $285,000. AlphaQuest LLC owned about 0.14% of Electromed at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the business. EntryPoint Capital LLC purchased a new position in Electromed during the first quarter worth about $462,000. Quantbot Technologies LP lifted its holdings in shares of Electromed by 57.7% in the 1st quarter. Quantbot Technologies LP now owns 5,301 shares of the company's stock valued at $126,000 after buying an additional 1,939 shares during the period. Algert Global LLC raised its position in Electromed by 19.2% in the first quarter. Algert Global LLC now owns 13,041 shares of the company's stock worth $311,000 after acquiring an additional 2,101 shares in the last quarter. American Century Companies Inc. raised its holdings in shares of Electromed by 32.5% in the first quarter. American Century Companies Inc. now owns 31,062 shares of the company's stock worth $741,000 after acquiring an additional 7,624 shares during the last quarter. Finally, Russell Investments Group Ltd. lifted its position in shares of Electromed by 557.0% in the first quarter. Russell Investments Group Ltd. now owns 7,969 shares of the company's stock valued at $186,000 after acquiring an additional 6,756 shares in the last quarter. 40.82% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have recently commented on ELMD shares. Roth Capital upped their price objective on Electromed from $29.00 to $35.00 and gave the stock a "buy" rating in a report on Wednesday, August 27th. Loop Capital set a $36.00 price objective on shares of Electromed in a research report on Wednesday, August 27th. B. Riley raised Electromed to a "strong-buy" rating in a research report on Thursday, May 15th. Wall Street Zen downgraded Electromed from a "strong-buy" rating to a "buy" rating in a research note on Thursday, May 8th. Finally, Lake Street Capital started coverage on shares of Electromed in a research note on Wednesday, August 27th. They set a "buy" rating and a $36.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating and two have issued a Buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $36.25.

Electromed Trading Down 0.7%

ELMD traded down $0.16 during trading hours on Wednesday, hitting $23.79. The company's stock had a trading volume of 5,411 shares, compared to its average volume of 83,647. Electromed, Inc. has a fifty-two week low of $16.40 and a fifty-two week high of $35.56. The firm has a market capitalization of $198.62 million, a PE ratio of 31.72 and a beta of 0.54. The company has a 50-day simple moving average of $20.01 and a 200 day simple moving average of $22.01.

Electromed Company Profile

Electromed, Inc develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions.